KPCB CHINA

Thesis

KPCB China, founded in 2007 as an independent advisory arm of Kleiner Perkins, focuses on identifying and nurturing innovation within China's rapidly growing economy. The firm's investment thesis centers on Digital, Green Tech, and Life Science opportunities, targeting high-growth industries such as technology, internet, media, wireless communications, new consumer areas, healthcare, and greentech. KPCB China aims to foster economic development, employment growth, and industry innovation. Their strategy involves close collaboration among investment teams, utilizing deep expertise, rich experience, and a global network to support Chinese entrepreneurs. The firm has been directly investing in China since 2006, with partners active in the region since 1999. KPCB China has managed dedicated funds, including a USD 360 million fund launched in 2007 and KPCB China Fund II with a target of $250 million in 2011. While specific AUM for KPCB China is not public, the broader Kleiner Perkins firm reported $21 billion in AUM in 2026. The firm operates primarily in China with offices in Beijing and Shanghai, investing across various stages from seed to late-stage, private equity, and debt financing.

Related lists

• Seed-stage Healthcare investors
• Seed-stage Marketplaces investors
• Series A Healthcare investors